Infant Bacterial Therapeutics AB (publ) (IBT-B) — Cash Flow-to-Debt Ratio
Infant Bacterial Therapeutics AB (publ) (IBT-B) has a Cash Flow-to-Debt Ratio of -0.97x as of September 2025, meaning its operating cash flow of Skr-52.25 Million could theoretically repay -1% of its total liabilities (Skr53.87 Million) in one year. See IBT-B financial flexibility score to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Infant Bacterial Therapeutics AB (publ) Cash Flow-to-Debt Ratio (2014–2024)
Historical debt coverage capacity for Infant Bacterial Therapeutics AB (publ) across 11 annual periods. For the full cash flow conversion analysis, see how efficiently does Infant Bacterial Therapeutics AB (publ) generate cash.
Annual Cash Flow-to-Debt Ratio for Infant Bacterial Therapeutics AB (publ) (2014–2024)
Year-by-year debt coverage analysis for Infant Bacterial Therapeutics AB (publ). Check how high is Infant Bacterial Therapeutics AB (publ)'s earnings quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.63x | Skr-113.13 Million | Skr69.30 Million | ▲ +25.5% |
| 2023 | -2.19x | Skr-101.22 Million | Skr46.18 Million | ▲ +54.2% |
| 2022 | -4.79x | Skr-85.80 Million | Skr17.91 Million | ▼ -13.9% |
| 2021 | -4.21x | Skr-55.62 Million | Skr13.22 Million | ▲ +26.8% |
| 2020 | -5.74x | Skr-58.39 Million | Skr10.16 Million | ▲ +11.8% |
| 2019 | -6.51x | Skr-51.30 Million | Skr7.88 Million | ▲ +8.6% |
| 2018 | -7.12x | Skr-47.41 Million | Skr6.65 Million | ▼ -36.4% |
| 2017 | -5.23x | Skr-34.76 Million | Skr6.65 Million | ▲ +35.8% |
| 2016 | -8.14x | Skr-39.75 Million | Skr4.88 Million | ▼ -269.8% |
| 2015 | -2.20x | Skr-17.02 Million | Skr7.73 Million | ▼ -104.6% |
| 2014 | -1.08x | Skr-3.77 Million | Skr3.51 Million | — |